Verona Pharma plc (VRNA) Announces Positive Phase 2 Results with pMDI Formulation of Ensifentrine in COP

Go back to Verona Pharma plc (VRNA) Announces Positive Phase 2 Results with pMDI Formulation of Ensifentrine in COP
(NASDAQ: VRNA) Delayed: 5.80 -0.13 (2.19%)
Previous Close $5.93    52 Week High
Open $5.83    52 Week Low
Day High $5.99    P/E N/A 
Day Low $5.80    EPS
Volume 41,470